NCT02588053View on ClinicalTrials.gov

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

CompletedOBSERVATIONAL
Enrollment

85

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2019

Conditions
Multiple Sclerosis
Trial Locations (1)

80045

University of Colorado Anschutz, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02588053 - Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? | Biotech Hunter | Biotech Hunter